Overview

An Open-label, Single-arm, Multicenter Phase II Clinical Study： Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cancer

Status:
Not yet recruiting

Trial end date:
2027-07-30

Target enrollment:

Participant gender:

Summary

An Open-label, Single-arm, Multicenter Phase II Clinical Study： Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cancer.It's arm to evaluate the neoadjuvant treatment of Her2-positive Muscle-invasive Bladder Cancer in patients with objective response rate (ORR),Duration of response (DoR) , progression-free survival (PFS), overall survival (OS), and safety.

Phase:

Phase 2

Details

Lead Sponsor:

Tianjin Medical University Cancer Institute and Hospital

Collaborators:

Chongqing University Cancer Hospital
First Affiliated Hospital Xi'an Jiaotong University
Hunan Cancer Hospital
The Southwest Hospital of AMU
Tongji Hospital
Xiangya Hospital of Central South University
Xijing Hospital of Air Force Military Medical University